6908-52-7

Basic information

• Product Name: AKOS BAR-2293
• Synonyms: AKOS BAR-2293;4'-METHYL-BIPHENYL-4-ACETIC ACID;OTAVA-BB 1179124;[4-(4-Methylphenyl)phenyl]acetic acid;2-(4'-Methyl-[1,1'-biphenyl]-4-yl)acetic acid
• CAS NO: 6908-52-7
• Molecular Formula: C15H14O2
• Molecular Weight: 226.274
• Mol File: 6908-52-7.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AKOS BAR-2293(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BAR-2293(6908-52-7)
• EPA Substance Registry System: AKOS BAR-2293(6908-52-7)

Safety Data

• Hazardous Substances Data: 6908-52-7(Hazardous Substances Data)

Usage

General Description

AKOS BAR-2293 is a chemical compound that is listed under the Chemical Abstracts Service (CAS) registry. It is a white to light yellow crystalline powder with a molecular formula of C22H28Cl2O4 and a molecular weight of 429.36 g/mol. AKOS BAR-2293 is commonly used as a pharmaceutical intermediate or an organic building block in the synthesis of other compounds. It is also known by its chemical name, 21-(2,5-dichlorophenyl)-4,9,13-trioxo-3,4,8,9,12,13-hexahydro-2H-12-oxapenta [1,4]dioxacyclohexadecino[1,2-d]pyrimidine-14-carbonitrile. AKOS BAR-2293 should be handled and stored according to appropriate safety and handling guidelines to prevent any potential hazards.

Upstream product

• 106-38-7 para-bromotoluene 
• 124-38-9 carbon dioxide 
• 15738-23-5 sodium tetrakis(4-tolyl)borate 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 37859-24-8 2-(4-bromophenyl)acetyl chloride 
• 5720-05-8 4-methylphenylboronic acid 

Relevant articles and documents

THIAZOLOPIPERAZINE DERIVATIVES AND COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES COMPRISING THE SAME

The present invention provides a thiazolopiperazine derivative, and a pharmaceutical composition and a health functional food composition for preventing or treating autoimmune diseases containing the same as an active component. A compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention can have an effect of inhibiting lysophosphatidic acid 1 (LPA1) receptor activation, thereby being able to be usefully used as the pharmaceutical composition or the health functional food composition for preventing or treating LPA1-related diseases. In addition, it is possible to effectively prevent or treat not only autoimmune diseases, but also other immune-related diseases with similar mechanisms of occurrence by using the pharmaceutical composition and the health functional food composition.COPYRIGHT KIPO 2020

Visible-Light-Driven External-Reductant-Free Cross-Electrophile Couplings of Tetraalkyl Ammonium Salts

Cross-electrophile couplings between two electrophiles are powerful and economic methods to generate C-C bonds in the presence of stoichiometric external reductants. Herein, we report a novel strategy to realize the first external-reductant-free cross-electrophile coupling via visible-light photoredox catalysis. A variety of tetraalkyl ammonium salts, bearing primary, secondary, and tertiary C-N bonds, undergo selective couplings with aldehydes/ketone and CO2. Notably, the in situ generated byproduct, trimethylamine, is efficiently utilized as the electron donor. Moreover, this protocol exhibits mild reaction conditions, low catalyst loading, broad substrate scope, good functional group tolerance, and facile scalability. Mechanistic studies indicate that benzyl radicals and anions might be generated as the key intermediates via photocatalysis, providing a new direction for cross-electrophile couplings.

1, 3, 5 - cyclohexanetriol - cis - or organic boronic acid-stable siloxy inositol complex and organic synthetic reaction using a reagent art

PROBLEM TO BE SOLVED: To provide a stable ate-type complex of an organoboronic acid as a reagent for organic synthesis reaction; and manufacturing techniques thereof.SOLUTION: A stable ate-type complex of an organoboronic acid with scyllo-inositol or 1,3,5-cis-cyclohexanetriol comprises an anion represented by the specified general formula (I) or (II) as a constituent. In the formula, Rand Reach represent an alkyl group, alkenyl group, alkynyl group, aryl group, heterocyclic group or aralkyl group which may have substituents.